Hydrazinophthalazine
| Hydrazinophthalazine | |
|---|---|
| Drug class | |
 | |
| Class identifiers | |
| ATC code | C02DB |
| Mode of action | Smooth muscle relaxant |
| Legal status | |
| In Wikidata | |
Hydrazinophthalazines are a class of antihypertensive drugs characterized by a phthalazine ring system with a hydrazine group attached.[1] The most notable member of this class is hydralazine, a medication used to treat high blood pressure and heart failure. Hydrazinophthalazines act as direct-acting smooth muscle relaxants, primarily affecting resistance arterioles to cause vasodilation.[2] This pharmacological action results in decreased peripheral resistance and lowered blood pressure. While hydralazine is the most well-known compound in this class, other related drugs such as dihydralazine also belong to the hydrazinophthalazine family and exhibit similar antihypertensive properties. These compounds have been in clinical use since the mid-20th century, with hydralazine being discovered in the 1940s and approved by the FDA in 1953.[2]
Examples include:
Chemically, the latter two aren't phthalazines; but they are classified as such in the World Health Organization's Anatomical Therapeutic Chemical Classification System.[4]
References
[edit]- ^ Szász G, Budvári-Bárány Z (1991). "Hydrazinophthalazines". Pharmaceutical chemistry of antihypertensive agents. Boca Raton: CRC Press. pp. 260–261. ISBN 978-0-8493-4724-5.
- ^ a b "Hydralazine". DrugBank.
- ^ a b Bourreli B, Pinaud M, Passuti N, Gunst JP, Drouet JC, Remi JP (May 1988). "Additive effects of dihydralazine during enflurane or isoflurane hypotensive anaesthesia for spinal fusion". Canadian Journal of Anaesthesia = Journal Canadien d'Anesthesie. 35 (3 ( Pt 1)): 242–248. doi:10.1007/BF03010617. PMID 3383316.
- ^ "ATC/DDD Index 2021: code C02DB". WHO Collaborating Centre for Drug Statistics Methodology.
 | This antihypertensive-related article is a stub. You can help Wikipedia by expanding it. |